Patents Assigned to Merck
  • Carbonyl compounds
    Patent number: 8129373
    Abstract: Novel compounds of the formula (I), in which D, E, G, W, X, Y, T, R1 and R2 are as defined in Patent Claim 1, are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumors.
    Type: Grant
    Filed: June 17, 2010
    Date of Patent: March 6, 2012
    Assignee: Merck Patent GmbH
    Inventors: Christos Tsaklakidis, Dieter Dorsch, Werner Mederski, Bertram Cezanne, Johannes Gleitz
  • DNA sequence and recombinant production of the grass pollen allergen Phl p 4
    Patent number: 8128935
    Abstract: The present invention relates to the provision of the genetic sequence of the major grass pollen allergen Phl p 4. The invention also covers fragments, new combinations of partial sequences and point mutants having a hypoallergenic action. The recombinant DNA molecules and the derived polypeptides, fragments, new combinations of partial sequences and variants can be utilised for the therapy of pollen-allergic diseases. The proteins prepared by recombinant methods can be employed for the in vitro and in vivo diagnosis of pollen allergies.
    Type: Grant
    Filed: June 11, 2003
    Date of Patent: March 6, 2012
    Assignee: Merck Patent GmbH
    Inventors: Helmut Fiebig, Andreas Nandy, Roland Suck, Oliver Cromwell, Arnd Petersen, Wolf-Meinhard Becker
  • Metal complexes
    Patent number: 8129554
    Abstract: The present invention describes novel metal complexes. Compounds of this type can be employed as functional materials in a number of different applications which can be ascribed to the electronics industry in the broadest sense. The compounds according to the invention are described by the formulae (1) and (1a).
    Type: Grant
    Filed: July 24, 2006
    Date of Patent: March 6, 2012
    Assignee: Merck Patent GmbH
    Inventor: Jochen Schwaiger
  • Crystalline forms of MC4R agonist and process for synthesis
    Patent number: 8129413
    Abstract: The present invention relates to a process for producing N-{(1S)-1-[2-(1-{[(3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl]carbonyl}piperidin-4-yl)-5-chlorophenyl]ethyl}acetamide, and novel crystalline salts, hydrates, solvates, and polymorphic forms thereof.
    Type: Grant
    Filed: June 23, 2006
    Date of Patent: March 6, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Ralph Calabria, Yu Cheng, Russell R. Ferlita, Ashkan Kamali, Jerry A. Murry, David Mathre, Andrey V. Peresypkin, Karen Thompson, Jian Wang, Robert M. Wenslow
  • PYRROLIDINE-DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS
    Publication number: 20120053181
    Abstract: The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of ?3-adrenoceptor.
    Type: Application
    Filed: April 28, 2010
    Publication date: March 1, 2012
    Applicant: Merck Sharp & Dohme, Corp.
    Inventors: Peter Lin, Lehua Chang, Scott D. Edmondson
  • METHOD FOR PRODUCING HYDROPHILIC POLY-N-VINYLPYRROLIDONE AND USE THEREOF
    Publication number: 20120053254
    Abstract: The present invention relates to a process for the production of the largest possible spherical, monodisperse polyvinylpyrrolidone (PVP) seed particles in the micron range by dispersion polymerisation. The particles obtained in this way represent novel starting materials for the production of macroporous polymer particles, which can in turn be employed in preparative and analytical chromatography for protein preparation. They can also be employed as base material for further reactions. The novel process for the polymerisation of N-vinylpyrrolidone, which is inexpensive to carry out, gives particles having optimised quantities, such as monodispersity, sphericity and particle diameter, which can be employed in further reactions and have advantageous, in particular improved, properties for use in chromatographic separation methods.
    Type: Application
    Filed: April 27, 2010
    Publication date: March 1, 2012
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Matthias Joehnck, Daniel Scheid
  • CINNAMIC ACID ASCORBATES
    Publication number: 20120052028
    Abstract: The invention relates to specific cinnamic acid ascorbates and to the use thereof as UV filters which bond to the skin, and to a process for the preparation thereof, and to preparations comprising these compounds.
    Type: Application
    Filed: April 12, 2010
    Publication date: March 1, 2012
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Thomas Rudolph, Philipp Buehle
  • 3-(1,2,3-Triazol-4-yl) pyrrolo [2,3-b] pyridine derivatives
    Publication number: 20120053178
    Abstract: Compounds of the formula (I), in which R1, R2 and R3 have the meanings indicated in claim (1), are inhibitors of PDK1 and cell proliferation/cell vitality and can be employed for the treatment of tumours.
    Type: Application
    Filed: April 8, 2010
    Publication date: March 1, 2012
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Dieter Dorsch, Margarita Wucherer-Plietker, Thomas J.J. Mueller, Eugen Merkul
  • MEANS AND METHOD FOR THE DETERMINATION OF THE ALDEHYDE CONTENT
    Publication number: 20120052588
    Abstract: The invention relates to a means in the form of a test strip and a method for the rapid determination of the content of aldehydes in samples.
    Type: Application
    Filed: April 19, 2010
    Publication date: March 1, 2012
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Daniel Rupprecht, Stefanie Beil-Seidler, Berthold Wagner
  • Polypeptides for inducing a protective immune response against
    Patent number: 8124108
    Abstract: The present invention features polypeptides comprising an amino acid sequence structurally related to SEQ ID NO: 1 and uses of such polypeptides. SEQ ID NO: 1 is a truncated derivative of a full-length S. epidermidis polypeptide. The full-length naturally occurring polypeptide is referred to herein as full-length ORF1319e. A His-tagged derivative of SEQ ID NO: 1 was found to produce a protective immune response against S. epidermidis.
    Type: Grant
    Filed: January 18, 2008
    Date of Patent: February 28, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Annaliesa S. Anderson, Tessie McNeely, James C. Cook, III, William L. McClements, Donna L. Montgomery
  • Process for the preparation of ring compounds
    Patent number: 8124817
    Abstract: In a process for the preparation of ring compounds via a combinatorial synthesis, the reaction procedure is based on a Suzuki coupling, subsequent halo-demetallation and finally a further Suzuki coupling. The Suzuki couplings are each carried out with a boronic acid or a boronic acid ester. The reaction procedure uses provides novel ring compounds and uses novel synthesis units used for this purpose. The novel ring compounds are suitable for use as constituents in liquid-crystalline mixtures.
    Type: Grant
    Filed: October 19, 2010
    Date of Patent: February 28, 2012
    Assignee: Merck Patent GmbH
    Inventors: Detlef Pauluth, Peer Kirsch, Peter Baeuerle, Oliver Deeg
  • Materials for organic electroluminescent devices
    Patent number: 8124249
    Abstract: The present invention relates to novel materials which can be used in organic electronic devices, in particular electroluminescent devices, and are derivatives of fused aromatic systems.
    Type: Grant
    Filed: March 3, 2006
    Date of Patent: February 28, 2012
    Assignee: Merck Patent GmbH
    Inventors: Philipp Stoessel, Esther Breuning, Amir Hossain Parham
  • OLEDs with increased light yield
    Patent number: 8125145
    Abstract: The present invention relates to OLEDs which have at least one substrate, a 1st electrode, at least one organic light-emitting layer and a 2nd electrode, where either the substrate and the 1st electrode, the 2nd electrode or the substrate and the 1st and 2nd electrodes are transparent, which are characterised in that at least one transparent layer which contains transparent, preferably spherical particles, which protrude at least partially out of the at least one layer is arranged on the substrate and/or the transparent 2nd electrode, to processes for the production thereof, and to the use thereof, in particular in illumination devices and displays.
    Type: Grant
    Filed: December 6, 2006
    Date of Patent: February 28, 2012
    Assignee: Merck Patent GmbH
    Inventor: Bernd Fiebranz
  • Hydroxymethyl ether hydroisoindoline tachykinin receptor antagonists
    Patent number: 8124633
    Abstract: The present invention is directed to certain hydroxymethyl ether hydroisoindoline compounds which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, LUTS, depression, and anxiety.
    Type: Grant
    Filed: April 7, 2008
    Date of Patent: February 28, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Robert J. DeVita, Sander G. Mills, Jinlong Jiang, Andrew J. Kassick, Jianming Bao
  • Diaryl substituted alkanes
    Patent number: 8124628
    Abstract: The instant invention provides compounds of Formula II which are 5-lipoxygenase activating protein inhibitors. Compounds of Formula II are useful as anti-atherosclerotic, anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agents.
    Type: Grant
    Filed: April 6, 2007
    Date of Patent: February 28, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Lin Chu, Bing Li, Anthony K. Ogawa, Hyun O. Ok, Debra L. Ondeyka, Minal Patel, Rosemary Sisco, Feroze Ujjainwalla, Jinyou Xu
  • POROUS, MAGNETIC SILICA GEL MOLDED PARTS, PRODUCTION THEREOF, AND APPLICATION THEREOF
    Publication number: 20120043496
    Abstract: The present invention relates to porous, magnetic silica-gel mouldings having novel properties, by means of which separations of substances from reaction solutions and solid-phase reactions are simplified. In addition, a process for the preparation of these separation materials and possible applications thereof are described.
    Type: Application
    Filed: March 17, 2010
    Publication date: February 23, 2012
    Applicant: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG
    Inventors: Karin Cabrera Perez, Anita Leinert
  • RENIN INHIBITORS
    Publication number: 20120046293
    Abstract: The present invention relates to renin inhibitor compounds having the structure and their use in treating cardiovascular events and renal insufficiency.
    Type: Application
    Filed: October 10, 2011
    Publication date: February 23, 2012
    Applicant: Merck Frosst Canada Ltd.
    Inventors: CHRISTOPHER I. BAYLY, Austin C. Chen, Daniel Dube, Laurence Dube, Michel Gallant, Patrick Lacombe, Dwight MacDonald, Daniel McKay, David A. Powell, Erich L. Grimm
  • Novel Amino Azaheterocyclic Carboxamides
    Publication number: 20120046269
    Abstract: The invention provides novel substituted amino azaheterocyclic carboxamide compounds according to Formula (I), their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.
    Type: Application
    Filed: February 4, 2010
    Publication date: February 23, 2012
    Applicant: Merck Patent GmbH
    Inventors: Amanda E. Sutton, Ruoxi Lan, Thomas E. Richardson, David Perrey, Harold George Vandeveer, Bayard R. Huck, Srinivasa R. Karra, Xiaoling Chen, Lesley Liu-Bujalski, Andreas Goutopoulos, Frank Steiber, Brian L. Hodous, Hui Qiu, Reinaldo C. Jones, Brian H. Heasley
  • Cicletanine derivatives
    Patent number: 8119806
    Abstract: A compound having the structure wherein X is selected from the group consisting of: a bond, —NHCH2(CH2)nCH2OC(O)—, —CH2NHC(O)CH2NHC(O)—, —CH2OC(O)—, —OCH(CH3)OC(O)—, —OCH2OC(O)—, —O—, —NR1—, —CR1R3—, —(CH2)p—, —(CH2)qNR1C(O)—, —CHR5NR2C(O)—, —(CH2)qC(O)—, —(CH2)qC(O)NR1—, or a pharmaceutically acceptable salt thereof, and methods of using the compounds for treating hypertension.
    Type: Grant
    Filed: July 27, 2009
    Date of Patent: February 21, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Amjad Ali, Iyassu K. Sebhat, Christopher L. Franklin, Kathleen M. Rupprecht, Robert K. Baker, Ravi P. Nargund, Lin Yan, Pei Huo, Dong-Ming Shen, Nicoletta Almirante, Stefano Biondi, Massimiliano Ferrario, Alessia Nicotra
  • 2-[1-phenyl-5-hydroxy or methoxy-4alpha-methyl-hexahydrocyclopenta [ƒ]indazole-5-YL]ethyl phenyl derivatives as glucocorticoid receptor ligands
    Patent number: 8119681
    Abstract: The present invention is directed to 2-[1-phenyl-5-hydroxy or methoxy-4alpha-methyl-hexahydrocyclopenta[f]indazol-5-yl]ethyl phenyl derivatives of formula I (I) as glucocorticoid receptor ligands useful for treating a variety of autoimmune and inflammatory diseases or conditions. Pharmaceutical compositions and methods of use are also included.
    Type: Grant
    Filed: October 23, 2007
    Date of Patent: February 21, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Christopher J. Bungard, Jesse J. Manikowski, James J. Perkins, Robert Meissner